Shionogi's stroke drug fails mid-stage; Bayer's Hyrnuo gets expanded label in NSCLC

Shionogi's redasemtide fails Phase 2 stroke trial; Bayer's Hyrnuo expands FDA label; Tevard, Disc, InduPro, EMD Serono/PostEra & Frazier news.

Raccontata daendpoints.news